Table of Contents Table of Contents
Previous Page  272 / 916 Next Page
Show Menu
Previous Page 272 / 916 Next Page
Page Background


25th European Congress of Psychiatry / European Psychiatry 41S (2017) S238–S302

into intervention (


= 15) or control (


= 14) arm, including 736

patients (73% psychotic disorder, 63% male, 48


13 years). The

intervention aimed to improve the obesogenic environment using a

small change approachwith a focus on nutrition and physical activ-

ity. Primary outcomewas waist circumference (WC) after three and

twelve month’s intervention. Secondary outcomes were BMI and

metabolic syndrome.


General linear mixed models adjusted for age, gen-

der, housing facility and antipsychotic medication showed that

WC significantly decreased with 1.51 cm (95%CI =





= 0.07) in the intervention group compared to con-

trol group after three months and tended to remain lower with

1.28 cm (95%CI =

2.79; 0.23, Cohen’s


= 0.06) after twelvemonths.

Metabolic syndrome Z-score decreased after three months with

0.225 SD (95% CI =


0.096, Cohen’s


= 0.20), mainly due

to lower fasting glucose and WC. No significant effects were found

on BMI.


A small change approach targeting the obesogenic

environment of SMI residential patients reduces cardiometabolic


Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Paliperidone palmitate and quality of

life in schizophrenia

N.B. Juan Carlos

, B. Girela , A. Maria Angeles

Hospital de Motril, Department of Psychiatry, Granada, Spain

Corresponding author.

There is growing interest in the study of the quality of life of

mental disorders in general, and particularly in schizophrenia. The

quality of life is defined by the world health organization as the

perception that an individual has of his place in existence, in the

context of culture and value system in which they live and in rela-

tion to its objectives, their expectations, their rules, their concerns.

Paliperidone palmitate is a depot anti-psychotic treatmentmonthly

application is indicated for maintenance treatment of schizophre-

nia in adult patients. In this work the quality of life in 5 subjects

with a diagnosis of paranoid schizophrenia (less than 10 years of

diagnosis) is evaluated, all males, aged between 42 and 45 years

and with poor adherence to oral treatment. The patients received

an average of paliperidone palmitate 100mg/month. We evaluate

the quality of life at baseline and after 3months – BREF quality of life

(WHOQOL – BREF) Scale Quality of Life (QOLS) and WHO was used.

The results showed significant improvements in major QOLS scale

in all subjects. There were no significant differences in total score

WHOQL – BREF scale, but if there was improvement in the scores

of some subscales. They no side effects evaluated in the UKU scale.

The quality of life in schizophrenic patients can be affected by the

presence of, particularly cognitive and negative clinical symptoms.

New treatments as paliperidone palmitate improve adherence and

have fewer side effects can improve the perceived quality of life.

However, they need more extensive studies double-blind evalua-


Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Effect of long-acting injectable

aripiprazole in glucose and lipids:

A 1 year study

M. Juncal Ruiz

1 ,

, O. Porta Olivares



B. Fernández-Abascal Puente


, M. Gómez Revuelta



R. Landera Rodríguez


, G. Pardo de Santayana Jenaro



L. Sánchez Blanco

1 , M.

Pérez Herrera

1 , D.

Abejas Díez

1 ,

J.L. García Egea



Hospital Universitario Marqués de Valdecilla, Psychiatry,

Santander, Spain


Hospital Universitario de Álava-Sede Santiago, Psychiatry,

Vitoria-Gasteiz, Spain


Hospital Universitario Virgen del Rocío, Psychiatry, Sevilla, Spain

Corresponding author.


Atypical anti-psychotics are associated with an

impaired in glucose and lipids homeostasis.


To evaluate, the effect in lipids and glucose levels after

switching to long-acting injectable (LAI) aripiprazole.


This was a prospective, observational, 1 year study car-

ried out in 125 outpatients with schizophrenia who were clinically

stabilized but a switching to another anti-psychotic was indicated.

We measured basal levels of glucose and lipids at the time to start

the study and 1 year after switching to LAI-aripiprazole.


Inbasal analyticwe observed these abnormalities: hyper-

glycemia (16.7%), high-levels of LDL-cholesterol (33.3%), low-levels

of HDL-cholesterol (39%) and hypertrygliceridemia (22.2%). One

year after switching to LAI-aripiprazole we found: glucose levels

were normalized in all patients; levels of LDL-cholesterol were

lower in 66.7% (in 33.3% levels were normalized) and they were

higher in 16.7% (in 11% marked a change from normal to abnormal

parameters); levels of HDL-cholesterol were lower in 23.3% and

higher in 32.2% (in 11% levels were normalized); and finally, levels

of tryglicerides were higher in 66.7% (in 8% marked a change from

normal to abnormal parameters) and in 16.7% they were lower (in

7.3% levels were normalized).


LAI-aripiprazole has a beneficial effect in glucose and

cholesterol levels. Although, it usually increases tryglicerides levels,

only in seven cases there was a change from normal to abnormal

parameters. Our study suggests that LAI-aripiprazol could be an

alternative in patients with schizophrenia who have high levels of

glucose and lipids related with atypical anti-psychotics treatment.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Risk factors related to homicide in

Moroccan patients with schizophrenia

A. Kachouchi

1 ,

, D.S. Majda


, D.S. Said


, P.A. Imane



P.M. Fatiha


, P.A. Mohamed


, P.A. Fatima



University hospital Mohammed VI, Department Of Psychiatry,

Marrakech, Morocco


University hospital Mohammed VI, Clinical research unit,

Mohammed VI university hospital/Community Medicine and Public

Health department, Marrakech, Morocco

Corresponding author.


The relationship between schizophrenia and homi-

cide is complex and cannot be reduced to a simple causal link.


The objectives of this study were to describe the

characteristics of homicide in Moroccan patients suffering from

schizophrenia and to determine the correlated socio-demographic,

clinical and toxic variables.


The study included two groups of patients with a

DSM-IV diagnosis of schizophrenia who attended the “Ibn Nafis”

university psychiatric hospital of Marrakech in Morocco. The first

group was composed of 30 patients hospitalized for homicide in

the forensic unit between the first January 2005 and the 31st of

August 2015. The second group included 90 patients without any

criminal record. These two groups have been matched according

to age and gender. Demographic, clinical and therapeutic variables

were analyzed and compared between the two groups.


The mean of age in the first group was 37.03 and in

the second group was 31.4. No significant difference was found